



CONCORD DRUGS LIMITED

(A PHARMACEUTICAL FORMULATIONS UNIT)

CORPORATE OFFICE : # 3-11-1/1, L.B. Nagar, Hyderabad - 500 074. A.P. India.

Tel : 091-40-24037763, 24036379

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2012

Rs in Lakhs

Sl. No.	Particulars	Three months	Three months	Three months	Year Ended
		30.6.2012	31.3.2012	30.06.2011	31.03.2012
		Un- Audited	(Audited)	(Un-Audited)	(Audited)
1	Income from Operations :	690.21	717.24	669.24	2,766.85
	(a) Net Sales / Income from Operations	-	0.40	1.50	3.30
	(b) Other Operating Income	690.21	717.64	670.74	2,770.15
	Total Income From operations (net)	-	-	-	-
2	Expenses :	13.22	13.42	10.26	48.14
	a) Operating Expenses	579.21	572.13	556.23	2,255.97
	b) Purchases of stock in trade				
	c) Changes in inventories of finished goods Work-in-progress and stock-in-goods	(0.50)	12.48	2.25	29.87
	d) Employee benefits expense	7.24	5.79	6.12	23.20
	e) Depreciation and amortisation expense	17.35	16.31	14.52	59.87
	f) Power And Fuel	10.25	6.22	5.23	22.77
	g) Freight and Forwarding Expenses	3.65	3.30	3.45	13.38
	h) Other Expenses	18.92	16.40	14.20	59.00
	Total Expenses (a+b+c+d+e+f+g+h)	649.34	646.05	612.26	2,512.20
	Profit/(Loss) from operations before other income and	40.87	71.59	58.48	257.95
3	Finance costs (1-2)	-	-	-	-
4	Other Income	-	-	-	-
5	Profit/(Loss) From ordinary activities before finance Cost (3+/-)4)	40.87	71.59	58.48	257.95
6	Finance cost	12.25	10.42	9.25	39.42
7	Profit/(Loss) from ordinary activities before Tax (5+/-)6)	28.62	61.17	49.23	218.53
8	Tax expenses	-	13.72	10.00	43.72
	(a) Current Tax	10.00	3.34	4.00	15.34
	(b) Deferred Tax	10.00	17.06	14.00	59.06
	Total (a+b)	18.62	44.11	35.23	159.47
9	Net profit/(loss) for the period (7+/-)8)	-	-	-	-
10	Minority interest	-	-	-	-
11	Net Profit/(Loss) after Taxes and minority interest (9+/-)10)	18.62	44.11	35.23	159.47
12	Paid up Equity Share Capital (Face value of Rs.10/- per share)	724.38	724.38	724.38	724.38
13	Reserves excluding Revaluation Reserve as per balance sheet at year end	-	-	-	399.69
14	Earnings Per Share (of Rs.10/- each) (not annualised)				
	a) Basic	0.26	0.61	0.49	2.20
	b) diluted	0.26	0.61	0.49	2.20



Part II
Select Information for the Quarter Ended 30/06/2012

Sl. No.	Particulars	Three months	Three months	Three months	Year Ended
		30.6.2012	31.3.2012	30.06.2011	31.03.2012
1	Public Shareholding				
	- Number of shares (000's)	4403250	4403250	4403250	4403250
	- Percentage of Shareholding	60.79%	60.79%	60.79%	60.79%
	Promoter and Promoter group				
2	Shareholding(ExcludingGDRS)				
	a) Pledged/Encumbered				
	- Number of Shares (000's)	--	--	--	--
	- Percentage of shares (As a % of total shareholding of Promoter and promoter group	--	--	--	--
	- Percentage of shares (As a % of total share Capital of the Company	--	--	--	--
	b) Non-Encumbered				
	- Number of Shares (000's)	2840500	2840500	2840500	2840500
	- Percentage of shares (As a % of total shareholding of Promoter and promoter group	100.00%	100.00%	100.00%	100.00%
	- Percentage of shares (As a % of total share Capital of the Company	39.21%	39.21%	39.21%	39.21%
	Particulars	The Quarter ended 30/06/2012			
B	INVESTOR COMPLAINTS				
	Pending at the beginning of the quarter	NIL	NIL		
	Received during the quarter	NIL	NIL		
	Disposed of during the quarter	NIL	NIL		
	Remaining unresolved at the end of the quarter	NIL	NIL		

NOTES:

- The above results for the quarter ended 30.06.2012 were reviewed by the Audit Committee at its meeting held on 13.08.2012 and approved by the Board of Directors in the meeting held on 13.08.2012. The statutory auditors of the Company have conducted limited review of these results.
- The Accounting Standard 17 relating to Segment wise reporting is not applicable as the company operates in only one segment viz., Pharmaceuticals
- Previous period's figures have been reclassified / regrouped / rearranged wherever necessary to confirm to current quarter presentation. The figures for the quarter ended March 2012 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures upto the previous quarter.

Place: Hyderabad
Date: 12.08.2012

For Concord Drugs Limited

S. Nagi Reddy
Managing director

